Product
SARS-CoV-2 Protein Subunit Recombinant Vaccine
1 clinical trial
2 indications
Indication
Adverse Reaction to ImmunizationIndication
Adverse Vaccine ReactionClinical trial
A Phase III, Observer-Blind, Randomized, Controlled Study of the Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine in Healthy Children Aged 12-17 Years in IndonesiaStatus: Recruiting, Estimated PCD: 2023-12-31